Related Experiment Video
Updated: Aug 9, 2025

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers
Elizabeth A Spencer1, Jami Kinnucan2, Julie Wang3
1Department of Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background:
Ustekinumab is approved for Crohn's disease and Ulcerative colitis with acute infusion reactions reported at a rate of 0.9%-4.5%.
Methods:
A retrospective chart review was conducted on inflammatory bowel disease (IBD) patients experiencing an acute infusion reaction to ustekinumab at 2 large institutions.
Results:
Acute ustekinumab infusion reactions occurred in 16 patients with Crohn's disease (CD) and Ulcerative colitis (UC), at a rate of 0.8%-3%. Patients were all naïve to ustekinumab, receiving their initial IV induction. Ninety-three percent subsequently tolerated the injection without issues.
Conclusions:
In this large, real-world study of acute infusion reactions to ustekinumab, the rate was similar to that seen in clinical trials-0.8%-3%.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Allergic Drug Reactions
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Acute Pyelonephritis II: Diagnostic Studies and Management
Kidney Transplant II: Surgical Procedure

